Avillion elects Ulf Wiinberg, CEO of Lundbeck, as Chairman of its Board of Directors

18-Jun-2014 - United Kingdom

Avillion LLP, a drug development company focused on co-development and financing of late-stage pharmaceutical candidates from Phase 3 clinical development to marketing approval, is pleased to announce that Ulf Wiinberg has been elected as Chairman of its Board of Directors.
 
Mr Wiinberg is Chief Executive Officer (CEO) of H. Lundbeck A/S, a position he has held since June 2008. Before joining Lundbeck, he worked at Wyeth/Lederle for 27 years, most recently as President of Wyeth Europe and Wyeth BioPharma. He is presently a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturer Association (IFPMA), Pharmaceutical Research and Manufacturers of America (PhRMA). In Denmark, Mr Wiinberg serves on the Industrial Policy Committee under the Confederation of Danish Industry, and he is a member of the board of directors of Alfa Laval, a large Public Company In Sweden.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances